Digital Health Benchmarking, Clinical Confirmation and Lifecyle Validation

The Food and Drug Administration is seeking to establish a comprehensive end-to-end capability for the management of innovative digital health medical devices. This initiative focuses on three primary pillars: premarket review, evaluation science, and postmarket oversight. The goal is to create a robust infrastructure for assessing the safety and efficacy of digital health technologies throughout their entire lifecycle. To achieve this, the program will develop essential technical assets including clinically grounded failure-mode taxonomies, benchmark design principles, and standardized evaluation protocols. Key deliverables involve the creation of reusable test sets, methods for weighting clinically consequential errors, and frameworks for analyzing subgroups and use-contexts. Additionally, the contract will establish formal processes for assessing digital health confirmation and monitoring performance following software updates.